The Perils of Merging Pharmaceutical Quality Systems
This article was originally published in The Gold Sheet
Executive SummaryThe mergers and acquisitions that drug makers are pursuing to obtain relief from today’s economic pressures could jeopardize quality assurance if not handled well, experts told a conference last month.
You may also be interested in...
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?
The Quality Lowdown: Warning Letters, Nitrosamine Recalls And Sen. Warren's Generics Manufacturing Plan
Manufacturers warned on quality basics like testing and keeping records and reminded about nitrosamine deadlines; Senator Elizabeth Warren clarifies government drug manufacturing idea.